WO2004038043A3 - POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS - Google Patents

POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS Download PDF

Info

Publication number
WO2004038043A3
WO2004038043A3 PCT/GB2003/004602 GB0304602W WO2004038043A3 WO 2004038043 A3 WO2004038043 A3 WO 2004038043A3 GB 0304602 W GB0304602 W GB 0304602W WO 2004038043 A3 WO2004038043 A3 WO 2004038043A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphism
diagnosis
indicator
treatment
sleep disorders
Prior art date
Application number
PCT/GB2003/004602
Other languages
French (fr)
Other versions
WO2004038043A2 (en
Inventor
Simon Archer
Schantz Malcolm Von
Josephine Arendt
Original Assignee
Univ Surrey
Simon Archer
Schantz Malcolm Von
Josephine Arendt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224928A external-priority patent/GB0224928D0/en
Priority claimed from GB0313480A external-priority patent/GB0313480D0/en
Application filed by Univ Surrey, Simon Archer, Schantz Malcolm Von, Josephine Arendt filed Critical Univ Surrey
Priority to AU2003278333A priority Critical patent/AU2003278333A1/en
Publication of WO2004038043A2 publication Critical patent/WO2004038043A2/en
Publication of WO2004038043A3 publication Critical patent/WO2004038043A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a polymorphism in the Per3 gene and to uses of that polymorphism to detect and treat extreme diurnal preference disorders.
PCT/GB2003/004602 2002-10-25 2003-10-24 POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS WO2004038043A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003278333A AU2003278333A1 (en) 2002-10-25 2003-10-24 Polymorphism in the per3 gene as a indicator in the diagnosis and treatment of circadian rhythm sleep disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0224928.2 2002-10-25
GB0224928A GB0224928D0 (en) 2002-10-25 2002-10-25 Polymorphism
GB0313480.6 2003-06-11
GB0313480A GB0313480D0 (en) 2003-06-11 2003-06-11 Polymorphism

Publications (2)

Publication Number Publication Date
WO2004038043A2 WO2004038043A2 (en) 2004-05-06
WO2004038043A3 true WO2004038043A3 (en) 2004-06-24

Family

ID=32178881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/004602 WO2004038043A2 (en) 2002-10-25 2003-10-24 POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS

Country Status (2)

Country Link
AU (1) AU2003278333A1 (en)
WO (1) WO2004038043A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036257A1 (en) * 2007-09-13 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075669A1 (en) * 1999-06-08 2000-12-14 Aventis Pharmaceuticals Inc. Screening methods for altering circadian rhythm proteins
WO2002055667A2 (en) * 2001-01-11 2002-07-18 Univ Utah Res Found Identification of an advanced sleep phase syndrome gene in humans

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075669A1 (en) * 1999-06-08 2000-12-14 Aventis Pharmaceuticals Inc. Screening methods for altering circadian rhythm proteins
WO2002055667A2 (en) * 2001-01-11 2002-07-18 Univ Utah Res Found Identification of an advanced sleep phase syndrome gene in humans

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCHER S ET AL: "A length polymorphism in the circadian clock gene PER3 is linked to delayed sleep syndrome and extreme diurnal preference", SLEEP, vol. 26, no. 4, 15 June 2003 (2003-06-15), pages 413 - 15, XP008029828 *
EBISAWA T ET AL: "Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome", EMBO REPORTS, vol. 21, no. 4, 2001, pages 342 - 46, XP002277121 *
IWASE T ET AL: "Mutation screening of the human Clock gene in circadian rhythm sleep disorders", PSYCHIATRY RESEARCH, vol. 109, no. 2, 15 March 2002 (2002-03-15), pages 121 - 8, XP002277122 *

Also Published As

Publication number Publication date
AU2003278333A8 (en) 2004-05-13
AU2003278333A1 (en) 2004-05-13
WO2004038043A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
IL179828A0 (en) Therapeutic agents for the treatment of hmgb1-related pathologies
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
AU2003275029A8 (en) Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
EP2286837A3 (en) Treatment of obesity and obesity related diseases
EP1670485A4 (en) Treatment of diseases associated with the egr-1 enhancer element
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2007073478A8 (en) Genemap of the human genes associated with crohn's disease
WO2006018632A3 (en) Cell therapy with exo 1
ZA200606834B (en) 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer's disease
WO2006058202A3 (en) Mer diagnostic and therapeutic agents
NO20054913D0 (en) Use of clustein for the treatment and / or prevention of peripheral neurological disorders
DE50305587D1 (en) 2-heteroarylcarbonsäureamide
WO2003078430A8 (en) Amides of acetic and propionic acids
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
WO2006063703A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
EP1553955A4 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2004038043A3 (en) POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS
WO2003070169A3 (en) Aminodiphosphonate apolipoprotein e modulators
WO2005108605A3 (en) Polymorphisms in abcb1 associated with a lack of clinical response to medicaments
WO2004089982A3 (en) April variants and methods thereof
EP2150627A4 (en) Polymorphism in the apo (a) gene predict responsiveness to acetylsalicylic acid treatment
WO2005104834A3 (en) Pain-associated gene pnpg5
AU2003240253A1 (en) Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
DE60222669D1 (en) ASTHMA ASSOCIATED GEN

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP